Contact Us
Drug Search Results
More Filters [+]

Pexacerfont

Alternative Names: pexacerfont, bms-562086, bms562086, bms 562086
Latest Update: 2023-04-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CRFR Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pexacerfont

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Generalized anxiety disorder

Phase 2: Alcoholism|Depressive Disorder, Major|Alcohol-Related Disorders|Irritable Bowel Syndrome

Phase 1: Taste Disorders|Hypertension|Weight Loss|Overweight

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
12-DA-N475

P1

Terminated

Taste Disorders|Overweight|Weight Loss|Hypertension

2015-09-01

11-AA-0010

P2

Completed

Alcohol-Related Disorders|Alcoholism

2014-07-01

CN148-015

P3

Completed

Generalized anxiety disorder

2008-03-01

CN148-007

P2

Completed

Depressive Disorder, Major

2007-10-01

Recent News Events

Date

Type

Title

04/01/2023

PubMed

 Corticotropin-Releasing Factor receptor 1 (CRF1) antagonism in patients with alcohol use disorder and high anxiety levels: effect on neural response during Trier Social Stress Test video feedback.

05/23/2021

PubMed

 Current Intervention Treatments for Food Addiction: A Systematic Review.

01/15/2021

PubMed

 T4-mediated rescue of aortic malformations in hypothyroid rats indicates maternal thyroid status can affect great vessel development.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions